Surrozen Inc Ordinary Shares SRZN 深 滬
等待開盤 10-31 09:30:00 美东时间
13.65
+0.060
+0.44%
華盛通- 最 高14.00
- 今 開13.42
- 成交量 2.93万股
- 最 低 13.42
- 昨 收 13.59
- 總市值 1.17亿
- 52周最高 18.17
- 市盈率 靜 --
- 換手率 0.34%
- 52周最低 5.90
- 委 比 0.00%
- 總股本 856.26万
- 歷史最高 210.00
- 量 比 6.76
- 振 幅 4.27%
- 歷史最低 4.50
- 每 手 1
- 風險率 1.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Surrozen’s Collaboration Agreement with TCGFB Terminated
The latest announcement is out from Surrozen ( ($SRZN) ). On October 14, 2025, ...
10-18 04:27
Surrozen Announces Termination Of Collaboration Agreement With TCGFB, Effective November 13, 2025; No Side To Incur Any Termination Penalties
On October 14, 2025, Surrozen, Inc. (the "Company") received notice from TCGFB, Inc. ("TCGFB") that TCGFB has elected to terminate the Collaboration Agreement (the "Collaboration Agreement") between TCGFB and the
10-18 04:25
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Surrozen, a biotech company focusing on治疗严重眼病的靶向疗法，于9月2日向四位新员工授予总计45,710股的股票期权。这些期权的行权价为每股12.32美元，归属期为4年，分月归属。此举措符合纳斯达克上市规则，并需员工持续服务至各归属日期。选项已由公司薪酬委员会批准，作为吸引新员工加入的激励措施。
09-04 20:15
Surrozen Signs $50M Sales Agreement with TD Securities
The latest update is out from Surrozen ( ($SRZN) ). On August 29, 2025, Surroze...
08-30 05:15
Surrozen GAAP EPS of $2.55
Surrozen press release (NASDAQ:SRZN): Q2 GAAP EPS of $2.55. Net: Other income, net was $16.2 million, compared to $3.7 million for the same period in 2024. The variance is primarily attributable to a ...
08-12 03:12
Surrozen’s Q2 2025: Progress in Eye Disease Therapies
Surrozen, Inc. ( ($SRZN) ) has released its Q2 earnings. Here is a breakdown of...
08-09 12:18
Surrozen Q2 EPS $2.55 Beats $(1.11) Estimate, Sales $983.000K
Surrozen (NASDAQ:SRZN) reported quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $(1.11) by 329.73 percent. This is a 131.91 percent increase over losses of $(7.99) per share from the
08-09 04:09
Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update
Surrozen, a biotech company focused on Wnt pathway therapeutics for severe eye diseases, reported Q2 2025 results. Key highlights include专利授予，领导层任命，临床咨询委员会成立，科学展示以及财务表现。Daniel Chao博士加入担任临床开发负责人。Surrozen ophthalmology pipeline continues with SZN-8141 and SZN-8143 candidates, targeting retinal diseases. Financially, the company had $90.4 million in cash, increased R&D expenses, and net income of $39.7 million. Dr. Craig Parker emphasized momentum i...
08-08 20:05
Surrozen to Present at Upcoming Healthcare Investor Conference
Surrozen, Inc. will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. The presentation will begin at 7:00 AM Eastern Time and can be accessed via the Investors section of Surrozen's website. The company specializes in developing tissue-specific antibodies targeting the Wnt pathway for severe eye diseases.
08-06 20:30
